<SEC-DOCUMENT>0001193125-18-294668.txt : 20181005
<SEC-HEADER>0001193125-18-294668.hdr.sgml : 20181005
<ACCEPTANCE-DATETIME>20181005162000
ACCESSION NUMBER:		0001193125-18-294668
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181005
FILED AS OF DATE:		20181005
DATE AS OF CHANGE:		20181005

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ascendis Pharma A/S
		CENTRAL INDEX KEY:			0001612042
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36815
		FILM NUMBER:		181110604

	BUSINESS ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
		BUSINESS PHONE:		45 70 22 22 44

	MAIL ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d587262d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO <FONT STYLE="white-space:nowrap">SECTION&nbsp;13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-36815</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:24pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Ascendis Pharma A/S</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tuborg Boulevard 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">DK-2900</FONT> Hellerup </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Denmark </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT>
&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furnished as Exhibit 99.1 to this Report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> is the
convening notice for the Extraordinary General Meeting of Ascendis Pharma A/S (the &#147;Company&#148;), providing notice to the Company&#146;s shareholders of the Company&#146;s Extraordinary General Meeting to be held on November&nbsp;2, 2018 at
2:00 pm CET. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d587262dex991.htm">Convening Notice to Shareholders. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Ascendis Pharma A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: October&nbsp;5, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Wolff Jensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Wolff Jensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Senior Vice President, General Counsel</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d587262dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g587262dddddddddd.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice to convene Extraordinary General Meeting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is hereby given that an extraordinary general meeting of Ascendis Pharma A/S (the &#147;Company&#148;) will be held on: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>02 November 2018 at 2:00 pm CET </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual general
meeting will be held at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mazanti-Andersen Kors&oslash; Jensen, Amaliegade 10, <FONT STYLE="white-space:nowrap">DK-1256</FONT> Copenhagen K, Denmark
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agenda for the annual general meeting is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Election of Chairman of the Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Election of new Board Member </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Authorisation of the chairman of the meeting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Complete Proposals </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors proposes that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-at-law</FONT></FONT> Anders Carstensen is
elected as chairman of the general meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Martin Olin has resigned from the Board of Directors with effect as of 12&nbsp;September 2018. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors proposes that Lars Holtug is elected as member of the Board of Directors replacing Martin Olin in Class&nbsp;II, i.e. for a term
expiring at the annual general meeting to be held in 2020, so that, if so decided by the shareholders, the board of directors will consists of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;I</B>, with a term expiring at the annual general meeting to be held in 2019: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James I. Healy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jan M&oslash;ller Mikkelsen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lisa Morrison </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Wolff Jensen </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;II</B>, with a term expiring at the annual general meeting to be held in 2020: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Albert Cha </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Birgitte Volck </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lars Holtug </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lars Holtug has accepted to stand for election in
accordance with the above. Information about the current board members and Lars Holtug is available on the Company&#146;s website <U>www.ascendispharma.com</U>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors proposes to authorize the chairman of the meeting (with a right of substitution) on behalf of the Company to apply the Danish Business
Authority for registration of the resolutions passed and in this connection to make any such amendments and supplements to the application and the resolution, including the Company&#146;s articles of association and these minutes of the general
meeting, that may be required as a condition for registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151;oo0oo&#151; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposals are adopted by a simple majority of the votes cast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s nominal share capital currently amounts to DKK 42,032,522 consisting of 42,032,522 shares of DKK 1 nominal value. At the general meeting,
each share amount of DKK 1 nominal value carries one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Information:</U></B> The following information is available at the Company&#146;s
website <U>www.ascendispharma.com</U> as of 05 October 2018. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Notice to convene the extraordinary general meeting </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The aggregate number of shares and voting rights as at the date of the notice to convene the general meeting
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The documents that will be submitted at the general meeting, including a description of the proposed new member
of the Board of Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The agenda and the complete proposals for adoption </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Forms for voting by proxy or by mail </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The convening notice will also be forwarded in writing to all shareholders recorded in the register of owners who have requested such notification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder&#146;s right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder owns on
the registration date. The registration date is 26&nbsp;October 2018. The shares which the individual shareholder owns are calculated on the registration date on the basis of the registration of ownership in the Register of Owners as well as
notifications concerning ownership which the company has received with a view to update the ownership in the Register of Owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any
shareholder who is entitled to attend a general meeting and who wishes to attend must have requested an admission card from the Company as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Language: </U></B>The meeting will be conducted in English according to section 7 of the Articles of Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders, proxies and any accompanying adviser must have an admission card to attend the general meeting. Admission cards may be ordered on the
Company&#146;s website,<U> www.ascendispharma.com</U> or on the website of Computershare A/S, <U>www.computershare.dk</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Admission cards must be
ordered no later than 01 November 2018 at 12.00 a.m. (CET). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Proxy:</U></B> For the general meeting, shareholders may vote by proxy by presenting an
instrument of proxy, duly signed and dated. Proxy forms can be downloaded from the website of the Company, <U>www.ascendispharma.com</U>, and must be forwarded to Computershare A/S, Lottenborgsvej 26 D,
1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> floor, <FONT STYLE="white-space:nowrap">DK-2800</FONT> Kgs. Lyngby, Denmark, by mail or by fax no. + 45 45 46 09 98. Computershare must receive completed proxy forms no later than 01 November
2018 at 12.00 a.m. (CET). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxies may also be granted electronically on the Company&#146;s website, <U>www.ascendispharma.com</U>, or on the website of
Computershare A/S, <U>www.computershare.dk</U>, by using a Computershare username and password. Usernames and passwords will be sent to all shareholders by email. Electronic proxies must be granted no later than 01 November 2018 at 12.00 a.m. (CET).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Voting by mail:</U></B> Shareholders may - instead of voting in person at the ordinary general meeting - choose to vote by mail, i.e. voting in
writing prior to the general meeting. Any shareholder who chooses to vote by mail shall send the absentee vote to Computershare A/S, Lottenborgsvej 26 D, 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> floor,
<FONT STYLE="white-space:nowrap">DK-2800</FONT> Kgs. Lyngby, Denmark, by mail or by fax no. + 45 45 46 09 98. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Electronic voting: </U></B>It is also
possible to vote electronically on the website of Computershare A/S, <U>www.computershare.dk</U>, by using Computershare username and password. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order
to stay valid, the absentee vote must be received by Computershare A/S no later than 01 November 2018 at 12.00 a.m. (CET).&nbsp;Absentee voting forms can also be downloaded from the website of the Company, <U>www.ascendispharma.com</U>. Please note
that an absentee vote cannot be withdrawn. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that letters may be in the mail for several days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hellerup, 05 October 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">On
behalf of the Board of Directors </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Michael Wolff Jensen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairman </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g587262dddddddddd.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g587262dddddddddd.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $T WP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * $/&.W
M/UQ@'^N*%ITO;H)Z)Z\MMF,9BHZXZ#I[^E-+5]4NG_!'%-N-O>26O01G*8ZD
M#KC QBE%\]K)Q]0;BNJC;NVOR3,34_%'A_1E+:OKNDZ0JC.=1O[2RP -W_+Q
M(O;GC-;1P^)D[4\-*HNDDG;Y6BUIMOT.2MCL'AD_;8JG1Y=_>V^5D<;=?&;X
M8V>1)XX\/R;>UK>K>GCT6T23/X9KLI91F-3;"27;;];'B8CBWAW"_P 7-J<;
M=%'_ (*.:OOVC/A;9(QBUN[U%U!_=V.DWY)(&0 ]U!!'R>,[\>I%=U/AC-JJ
MTI*DNCD]O/W5+8\;$^)?"V%YE]9G7<5?W(P7R]Z:_(XNZ_:O\(Q,5M- UZX4
M9VR3/IUHC8Z=+B5E_%?SKOH<&9C+XZ]/UY9?DDCQZGBYDJ_W?+Z]>VR]I3A^
M3D8%Y^U?')&5L?"KP'#!9I=<B)&0<-Y8T.1<@\XSSCK6T>#<1";53$PM%[<D
MO\T>56\8*+;C1R6M!QT3=>F_3>DSA-2_:6\8W1VZ==G2B&!'[G1;W*J>547&
MCJ>G<@8S7IT>%,'3_BQ6(=G9*56%K+RJ?U8\7$^*&<5W&.&YL M=91PU5=+?
M%A]+?C?R/HCX(?%34?B'#J=KJ-G<M/I"0O+JX%L;.=YR MJPM;.W2"[51YOE
M@/F-PVX=*^=XAR2GE,J$J<X)5UI33ES1MS7?O-MK1*_1V[GZ/P+Q96XDIX^C
MB*%15<#42]M+V:C-.,;14:<8)--MZIW74]]KYD^_&E@IQTX^GM0_=5^B$Y1C
MI>S[ &'H>*5[<NFC_#U*M9+47..QX_I0FMK["6VUK"!ACN,<>G0XQ^E5:VA,
M9)K^6S:L^Z=OT ,,XZ$'&.E%FO1#3U:6O*[-]-D_U#<!CKZ?E1:WR"_9-V[=
M +!?4?\ UJ6S22OYK83E&#2;L!;&,*Q^@'&/7FDW;2S?H#ER]')=U_P6A-X'
MKQ^F*>B?+?5 I1M>_*EW%W#C /X=L4;.W]:#33V>G?H!8+[8_I32?W$\\8[O
MEMW%!_#]*5K?(M>EK"%POJ,?TJ5)7<5\2MIU\OO$VHJ[?*EW\C@_!7Q-\&?$
M./69?!^JMJ\/A_4Y-'U.9;*]M8H=0B4-)#$][;PBY"@@%XMZYXSFO2Q>68S
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MK2Y\6>*[GQ!9V$37)NK&S>WAA6'4%N+6%8KD2!^(FF4J =P)*CMXKS;!YG+
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M3Y6^(/\ P4IT8V$D'PM\#:JVIRIM35/')L;:TL6S]\:-H>J7;7[+U&=1M0<
M,&' ^EP7 .(4D\?C*2@FKPHJ<KI;KFG&G;33X7ZH^'S#Q=H0I5*>49;B.><6
ME4Q+I4U%V:3]G"5=2MN_?7;S/SV^(OQU^(GQ5OS?>-O$M]JB+@6^EHT=GHEB
M%+$?8](M!';0N&8D3&-IN!F1B,U]]E^3Y;E<8QP5#V+C]O15):WO*:7-)]KM
MV6BT/QK.LWSC/:OM,PQDYQ5[4XRG"DD]TJ2DX16FJ2L^QYJNJ9S[ CHHY*G
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M,Z+Y:C=E=3UFSLW)'HJ3,<GH :X<RK_5<!B:RT]G3F]=M(R:_([LLRR.)S#
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M5-.D!_O(OK7S7%N,5#)*\.M>=."W\T__ $K0^EX2RJ4\[PTNE%.73[+C)?\
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M6X59II)Y!)*(U<EY"3TC7B@"OJG@?1=5\5:-XPNHYFUC0K?[/8.L[K"B W9
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D H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
